Inventiva (IVA) Capital Expenditures (2019 - 2025)
Inventiva's (IVA) quarterly Capital Expenditures came in at -$64521.7 in Q2 2025, up 76.5% year-on-year from -$36555.4 in Q2 2024, and up 76.5% quarter-over-quarter from -$274606.3 in Q2 2024.
Inventiva (IVA) Capital Expenditures (2019 - 2025) Analysis & Trends
Inventiva's Capital Expenditures history runs 5 years deep, the most recent figure standing at -$64521.7 for Q2 2025.
- On a quarterly basis, Capital Expenditures rose 76.5% year-over-year to -$64521.7 in Q2 2025; TTM through Jun 2025 was -$949979.4, a 10.9% increase from a year earlier, with the FY2022 full-year figure at -$301993.2, down 67.08% from the prior year.
- Capital Expenditures advanced to -$64521.7 in Q2 2025 per IVA's latest filing, from -$274606.3 in the prior quarter.
- Across five years, Capital Expenditures topped out at -$49455.7 in Q1 2021 and bottomed at -$308858.1 in Q3 2022.
- The 4-year median for Capital Expenditures is -$180747.4 (2021), against an average of -$188726.0.
- Across the five-year window, Capital Expenditures sank 67.08% in 2022 and surged 76.5% in 2025, its largest moves.
- Year by year, Capital Expenditures stood at -$180747.4 in 2021, then sank by 67.08% to -$301993.2 in 2022, then increased by 9.07% to -$274606.3 in 2024, then jumped by 76.5% to -$64521.7 in 2025.
- Per Business Quant, the three latest IVA Capital Expenditures figures stand at -$64521.7 (Q2 2025), -$274606.3 (Q2 2024), and -$301993.2 (Q4 2022).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Inventiva | 842.48 Mn | 842.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -64,521.70 |
| Jun 30, 2025 | -64,521.70 |
| Jun 30, 2024 | -274,606.33 |
| Jun 30, 2024 | -274,606.33 |
| Dec 31, 2022 | -301,993.22 |
| Dec 31, 2022 | -301,993.22 |
| Sep 22, 2022 | -308,858.12 |
| Sep 22, 2022 | -308,858.12 |
| Dec 31, 2021 | -180,747.41 |
| Dec 31, 2021 | -180,747.41 |
| Jun 30, 2021 | -140,899.76 |
| Jun 30, 2021 | -140,899.76 |
| Mar 31, 2021 | -49,455.68 |
| Mar 31, 2021 | -49,455.68 |
| Dec 31, 2019 | -161,605.60 |
| Dec 31, 2019 | -161,605.60 |